Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + FOLFOXIRI in mCRC (OPAL)
NCT00940303Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2009
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Roche. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00940303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940303.